Q1 Earnings Estimate for Celcuity Issued By Leerink Partnrs

Celcuity Inc. (NASDAQ:CELC - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Celcuity in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings per share of ($0.83) for the quarter. The consensus estimate for Celcuity's current full-year earnings is ($2.62) per share. Leerink Partnrs also issued estimates for Celcuity's Q3 2025 earnings at ($0.98) EPS, Q4 2025 earnings at ($1.09) EPS, FY2025 earnings at ($3.77) EPS, FY2026 earnings at ($3.33) EPS and FY2027 earnings at $0.63 EPS.

Several other analysts also recently issued reports on CELC. HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Celcuity in a research report on Friday, November 15th. Needham & Company LLC raised their price objective on shares of Celcuity from $23.00 to $29.00 and gave the stock a "buy" rating in a report on Thursday, February 6th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $30.17.

Celcuity Trading Up 1.7 %

Shares of CELC traded up $0.21 during trading hours on Monday, hitting $12.62. 151,295 shares of the stock were exchanged, compared to its average volume of 232,541. The firm has a market capitalization of $468.58 million, a P/E ratio of -4.84 and a beta of 0.73. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. The business has a 50-day moving average of $12.27 and a 200-day moving average of $14.24. Celcuity has a fifty-two week low of $10.35 and a fifty-two week high of $22.19.

Institutional Investors Weigh In On Celcuity

Several institutional investors and hedge funds have recently bought and sold shares of CELC. Barclays PLC raised its stake in Celcuity by 6.7% in the fourth quarter. Barclays PLC now owns 57,199 shares of the company's stock worth $749,000 after buying an additional 3,594 shares in the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of Celcuity by 49.5% in the fourth quarter. Ameritas Investment Partners Inc. now owns 3,421 shares of the company's stock worth $45,000 after purchasing an additional 1,132 shares during the last quarter. Wells Fargo & Company MN raised its position in Celcuity by 81.7% in the 4th quarter. Wells Fargo & Company MN now owns 15,515 shares of the company's stock worth $203,000 after buying an additional 6,976 shares during the last quarter. Trexquant Investment LP bought a new position in Celcuity during the fourth quarter valued at approximately $152,000. Finally, Geode Capital Management LLC boosted its stake in shares of Celcuity by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 692,372 shares of the company's stock worth $9,065,000 after buying an additional 62,003 shares during the last quarter. Hedge funds and other institutional investors own 63.33% of the company's stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.